drugset / Trial / NCT00782301
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.
Timeline
- Start
- 2009-03
- Primary completion
- 2010-02
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etravirine | Small molecule | 200 mg | Oral |
| Comparator | Maraviroc | Other / unclassified | 150 mg | Oral |
| Comparator | Darunavir | Small molecule | 600 mg | Oral |
| Comparator | Raltegravir | Other / unclassified | 400 mg | Oral |
| Comparator | Ritonavir | Other / unclassified | 100 mg | Oral |